biomarker analysis News
-
Biomark to Present New Cancer Screening Data using the Ldtd-Ms/Ms Technique at The Annual Asms Conference on Mass Spectrometry
BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 – 9, 2022 ...
-
Focussing on Australia`s second biggest killer
The cluster will conduct the START (Stroke, imaging, pRevention and Treatment) cohort study of stroke which is designed to integrate imaging and biomarker analysis to identify patients at risk of stroke. Those strategies will then be used to develop preventative measures for those patients. The START Cohort will collect and analyse information derived from brain imaging and blood samples taken ...
-
908 Devices Names Kevin Hrusovsky, 30-year Biotechnology Veteran and Founder of Powering Precision Health, as Chairman of its Board of Directors
Life Sciences 908 Devices, a pioneer of purpose-built handheld and desktop Mass Spec devices for chemical and biomolecular analysis, today announced the appointment of Kevin Hrusovsky as the Chairman of its Board of Directors. Mr. Hrusovsky, who has served on the 908 Devices Board of Directors since 2013, is a biotech entrepreneur and healthcare visionary with a passion for revolutionizing ...
-
SomaGenics strengthens its IP and technology position in small RNA analysis and biomarker discovery with new patent and publication
Santa Cruz, CA, September 2018 - SomaGenics announced today the issue of US Patent 10,041,107, a continuation of SomaGenics’ patent family entitled “Methods and Compositions for Detection of small RNAs.” The new patent broads protection for SomaGenics’ innovative, circularization-based approaches to accurately detect and quantify small RNAs, including key ...
-
Veravas and Tymora Collaborate on Early Detection Alzheimer’s Testing
CHARLESTON,S.C. and OAKDALE, Minn., January, 13 2020, - Veravas, Inc. and Tymora Analytical Operations, LLC announced today that they have entered into a strategic alliance to explore the integration of their respective technologies. Veravas is an emerging diagnostic company focused on proprietary sample preparation products and new diagnostic tests. Tymora’s focus is on providing ...
-
Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use
Creative BioMart, one of the world leading biotechnology companies serving science, recently updated its R-PEAPC Conjugated Proteins offerings to meet different research needs and applications. R-PE Labeled Proteins are labeled products generated by combining R-PE fluorescent dyes with proteins. R-PE labeled protein is non-toxic, odorless, and has high stability. And when the excitation ...
-
CD Genomics: The Biomedical Bioinformatics Platform Unveils Biomarker and Target Discovery Data Analysis Service
The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the ...
By CD Genomics
-
CD Genomics Provides Integration Analysis of Whole-Genome Bisulfite and RNA Sequencing for Biomarker Research
CD Genomics, a genomics services company, has become one of the top providers in genomic research, devoting to providing reliable services to pharmaceutical and biotech companies as well as academia and government agencies. CD Genomics provides a wide range of services such as genome sequencing, RNA sequencing, epigenomics sequencing, genotyping, as well as integrated portfolios of multiple ...
By CD Genomics
-
Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...
By CD Genomics
-
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and ...
-
Bionano Genomics announces release of version 6.2 of its Nxclinical software with significant new capabilities for cancer research applications including HRD analysis
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the version 6.2 software release of NxClinical. ...
-
Creative Proteomics Lipidomics Announces Exosomes Lipidomics Service to Identify Lipid-based Biomarkers
Lipidomics, a division of Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology and pharmaceutical companies. The product manager has recently announced the fully-developed exosomes lipidomics service to help identify lipid-based biomarkers and unravel its monitoring function in diseases. ...
-
Creative Proteomics Lipidomics Launches Exosomes Lipidomics Service to Study the Biological Characteristics of Vesicles
Lipidomics, a division of Creative Proteomics, is committed to providing untargeted lipidomics services, targeted lipidomics services, metabolic flux analysis services, and lipidomics related services for research institutions, biotechnology and pharmaceutical companies. The company continues to accelerate lipidomics research to make contributions in the fields of biopharmaceuticals, population ...
-
Webinar #4: The CAM Assay: From Efficacy/Toxicity Studies to Mechanisms of Action Analysis
Webinar Description: Understanding the mechanisms of action of new drugs is a key success factor for efficient drug discovery. It’s necessary for: Anticipating problems relating to clinical safety Determining the site of interaction between a drug and a receptor Identifying which patients will respond to a given treatment Improving drug dosing Considering combinations or ...
-
Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions
Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...
-
PERKINELMER AND PREDICTIVE DIAGNOSTICS ANNOUNCE DISCOVERY OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...
-
Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to Collaborate on Companion Diagnostic Test for Analysis of Tumor PD-L1 Levels
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced a collaboration with Merck & Co., Inc. (known as MSD outside the United States and Canada, through an affiliate) to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this ...
-
Bastiaan van der Baan and Miro Venturi join Tethis as Independent Members of the Board of Directors
Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors. Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and ...
By Tethis S.p.A
-
OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION WHICH ENABLES LABORATORIES WITH NGS ...
By OncoDNA S.A.
-
Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you